{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T05:35:03Z","timestamp":1737956103263,"version":"3.33.0"},"reference-count":20,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Misuse"],"published-print":{"date-parts":[[2025,2,23]]},"DOI":"10.1080\/10826084.2024.2434006","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T05:47:43Z","timestamp":1733118463000},"page":"442-445","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Use of Diverted Buprenorphine by Individuals Initiating Telehealth Opioid Use Disorder Treatment"],"prefix":"10.1080","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-5184","authenticated-orcid":false,"given":"Scott G.","family":"Weiner","sequence":"first","affiliation":[{"name":"Bicycle Health, Boston, Massachusetts, USA"},{"name":"Department of Emergency Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily N.","family":"Miller","sequence":"additional","affiliation":[{"name":"Bicycle Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Clear","sequence":"additional","affiliation":[{"name":"Bicycle Health, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,12]]},"reference":[{"unstructured":"Ahmad F. B. Cisewski J. A. Rossen L. M. & Sutton P. (2024). Provisional drug overdose death counts. National Center for Health Statistics. Retrieved August 18 2024 from https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm","key":"e_1_3_2_2_1"},{"doi-asserted-by":"publisher","key":"e_1_3_2_3_1","DOI":"10.1016\/j.drugpo.2020.102722"},{"doi-asserted-by":"publisher","key":"e_1_3_2_4_1","DOI":"10.1080\/08897077.2021.1876199"},{"doi-asserted-by":"publisher","key":"e_1_3_2_5_1","DOI":"10.1001\/jamanetworkopen.2024.25999"},{"doi-asserted-by":"publisher","key":"e_1_3_2_6_1","DOI":"10.15585\/mmwr.mm7325a1"},{"issue":"194","key":"e_1_3_2_7_1","first-page":"62354","article-title":"Schedules of controlled substances: Rescheduling of buprenorphine from schedule V to schedule III. Final rule","volume":"67","author":"Drug Enforcement Administration (DEA), Department of Justice","year":"2002","unstructured":"Drug Enforcement Administration (DEA), Department of Justice. (2002). Schedules of controlled substances: Rescheduling of buprenorphine from schedule V to schedule III. Final rule. Federal Register, 67(194), 62354\u201362370.","journal-title":"Federal Register"},{"doi-asserted-by":"publisher","key":"e_1_3_2_8_1","DOI":"10.1001\/jamanetworkopen.2022.52381"},{"doi-asserted-by":"publisher","key":"e_1_3_2_9_1","DOI":"10.1007\/s11606-020-06257-4"},{"doi-asserted-by":"publisher","key":"e_1_3_2_10_1","DOI":"10.1016\/j.socscimed.2022.114992"},{"doi-asserted-by":"publisher","key":"e_1_3_2_11_1","DOI":"10.1111\/j.1533-2500.2010.00378.x"},{"doi-asserted-by":"publisher","key":"e_1_3_2_12_1","DOI":"10.1001\/jamapsychiatry.2023.0234"},{"doi-asserted-by":"publisher","key":"e_1_3_2_13_1","DOI":"10.1016\/j.josat.2023.209151"},{"doi-asserted-by":"publisher","key":"e_1_3_2_14_1","DOI":"10.1080\/10826084.2023.2177972"},{"doi-asserted-by":"publisher","key":"e_1_3_2_15_1","DOI":"10.1097\/ADM.0000000000001006"},{"doi-asserted-by":"publisher","key":"e_1_3_2_16_1","DOI":"10.1001\/jamanetworkopen.2022.51856"},{"doi-asserted-by":"publisher","key":"e_1_3_2_17_1","DOI":"10.1016\/j.amjmed.2023.11.004"},{"unstructured":"U.S. Department of Health & Human Services. (2022). Opioid prevention strategy. Evidence-based treatment. Retrieved August 18 2024 from https:\/\/www.hhs.gov\/overdose-prevention\/treatment","key":"e_1_3_2_18_1"},{"unstructured":"United States Drug Enforcement Agency. (2023). DEA and HHS extend telemedicine flexibilities through 2024. October 6. Retrieved August 18 2024 from https:\/\/www.dea.gov\/documents\/2023\/2023-10\/2023-10-06\/dea-and-hhs-extend-telemedicine-flexibilities-through-2024","key":"e_1_3_2_19_1"},{"doi-asserted-by":"publisher","key":"e_1_3_2_20_1","DOI":"10.1016\/j.jsat.2020.108272"},{"doi-asserted-by":"publisher","key":"e_1_3_2_21_1","DOI":"10.1001\/jamanetworkopen.2023.16089"}],"container-title":["Substance Use &amp; Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2024.2434006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T15:49:24Z","timestamp":1737906564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2024.2434006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,23]]}},"alternative-id":["10.1080\/10826084.2024.2434006"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2024.2434006","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"type":"print","value":"1082-6084"},{"type":"electronic","value":"1532-2491"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}